Alphamab Oncology released its mid-term report in 2024, showing revenue of RMB 173,561 thousand for the period, an increase compared to the same period last year, but still resulting in a loss of RMB 44,896 thousand for the period. During the reporting period, the company's R&D expenses were RMB 194,531 thousand, similar to the same period last year. The company is mainly engaged in the research, development, production, and commercialization of oncology biologics, and did not distribute dividends during the reporting period. As of June 30, 2024, the company's current assets were RMB 1,592,832 thousand, current liabilities were RMB 345,376 thousand, and the net assets were RMB 1,628,751 thousand.

Alphamab Oncology released its mid-term report in 2024, showing revenue of RMB 173,561 thousand for the period, an increase compared to the same period last year, but still resulting in a loss of RMB 44,896 thousand for the period. During the reporting period, the company's R&D expenses were RMB 194,531 thousand, similar to the same period last year. The company is mainly engaged in the research, development, production, and commercialization of oncology biologics, and did not distribute dividends during the reporting period. As of June 30, 2024, the company's current assets were RMB 1,592,832 thousand, current liabilities were RMB 345,376 thousand, and the net assets were RMB 1,628,751 thousand.